Helix Acquisition Corp. III Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Helix Acquisition Corp. III performed this year. Think of this as a cheat sheet to help you decide if this company fits your investment goals.

1. What does this company do?

Helix Acquisition Corp. III is a "blank check" company, also known as a SPAC. It doesn’t make products or provide services. Instead, it raised $172.5 million by selling 17,250,000 units at $10.00 each. Its goal is to find and merge with a private company to take it public. You aren’t investing in an operating business; you are betting on the management team’s ability to find a high-growth partner. They are specifically looking for companies in healthcare, biotech, and medical technology.

2. Financial performance

As a shell company, Helix generates no revenue. Its assets consist of $172.5 million held in a trust account, invested in safe, short-term government securities. The company pays for administrative costs—like legal, accounting, and listing fees—using loans from its sponsor, Cormorant Asset Management. Because of these ongoing costs, the company currently reports a loss.

3. Major wins and updates

• The Big Win: The company successfully launched on the Nasdaq on January 22, 2026, under the ticker "HXAC." It raised $172.5 million, which included the full amount offered to underwriters.
• Leadership: CEO Bihua Chen, who founded Cormorant Asset Management, leads the team. She and her team are using their deep industry connections to vet potential acquisition targets.

4. Financial health

The company is in a strong position. The $172.5 million in the trust account is reserved specifically for a future merger. These funds cannot be used for daily operations, so the company relies on loans from its sponsor to stay afloat. The team has 24 months from the IPO date to finish a deal. If they don’t finalize a merger by January 2028, they must return the money to shareholders.

5. Key risks

Investing in a SPAC is highly speculative. Here is what you should watch:

• The "Search" Risk: There is no guarantee they will find a target. If they fail to merge by the deadline, they must dissolve. You could lose the interest earned on your money or any premium you paid above the $10.00 value.
• Limited Say: The sponsor and early investors have agreed to vote in favor of a merger, regardless of how you vote.
• The "Bad Deal" Risk: The target company might be an early-stage business with little data or cash flow, which could hurt the share price later.
• Dilution: The sponsor bought millions of shares for a very low price. When a merger happens, these shares convert to common stock. This means more shares are issued, reducing your ownership percentage and voting power.
• No Guarantees: Past success doesn't guarantee future results. Also, the company must follow Nasdaq rules to stay listed; failing to do so could make it hard to sell your shares.

6. Future outlook

The team is currently scouting for healthcare companies that align with their goals. They want a partner with a strong management team and a clear path to success. Their success depends entirely on signing a deal before January 2028.

Final Thought for Investors: Investing in a SPAC like Helix is a bet on the management team’s track record and their ability to identify a high-potential healthcare company. Before buying in, ask yourself if you are comfortable with the two-year timeline and the inherent risks of a company that has yet to identify its partner. If you prefer companies with established revenue and proven products, this may not be the right fit for your portfolio.